Edwards Lifesciences
EW
$92.03
+2.57%
Edwards Lifesciences Corp is a global leader in structural heart disease medical devices, specializing in surgical tissue heart valves, transcatheter aortic valve replacement (TAVR), and transcatheter mitral and tricuspid therapies. The company holds a dominant market position in TAVR, with a strong pipeline and a reputation for innovation in minimally invasive heart valve technologies. Currently, the stock is in focus due to a proposed expansion of Medicare coverage for TAVR procedures, which could significantly broaden patient access, and a recent beat-and-raise quarter that highlighted robust demand for its heart valve therapies. The investor narrative centers on sustained growth from TAVR adoption, potential regulatory tailwinds, and the expansion of its transcatheter mitral and tricuspid portfolio.…
EW
Edwards Lifesciences
$92.03
Related headlines
Investment Opinion: Should I buy EW Today?
Based on the analysis, EW is rated a Buy. The company's strong revenue growth (16.7% YoY), high gross margins (78.2%), and positive regulatory catalyst support a bullish outlook. The average analyst target of $100.96 implies ~13% upside, and the consensus recommendation is 'Buy'.
Sign up to view all
EW 12-Month Price Forecast
The AI assessment is bullish on EW, driven by strong fundamentals and a favorable regulatory catalyst. The company's dominant position in TAVR and expanding product portfolio support sustained growth. However, the high valuation and competitive risks warrant a medium confidence level. If the company continues to deliver double-digit growth and the Medicare expansion is approved, the stock could outperform. Conversely, any signs of growth deceleration or competitive setbacks would lead to a downgrade to neutral.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Edwards Lifesciences's 12-month outlook, with a consensus price target around $100.96 and implied upside of +9.7% versus the current price.
Average Target
$100.96
0 analysts
Implied Upside
+9.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$84 - $110
Analyst target range
The target price range spans from a low of $84.00 to a high of $110.00, indicating a wide spread of $26, which reflects moderate uncertainty about the company's future performance. The high target of $110.00 suggests expectations of continued strong growth, possibly driven by TAVR market expansion and new product launches, while the low target of $84.00 implies concerns about competitive pressures or regulatory hurdles. Recent institutional ratings have been predominantly positive, with no downgrades, and the stock has seen a series of 'Outperform' and 'Buy' ratings, reinforcing the bullish sentiment. The wide range suggests that while the consensus is positive, there is meaningful divergence in expectations, which could lead to volatility.
Bulls vs Bears: EW Investment Factors
Edwards Lifesciences presents a compelling growth story with accelerating revenue, high margins, and a favorable regulatory catalyst. However, the stock trades at a premium valuation (trailing P/E 46.3x) and has underperformed the market, reflecting high expectations. The bull case is supported by strong fundamentals and analyst optimism, while the bear case centers on valuation risk and competitive threats. The most critical tension is whether the company can sustain double-digit growth to justify its premium multiple; if growth decelerates, the stock could face significant de-rating. Currently, the bull case has stronger evidence given the recent beat-and-raise and Medicare tailwind, but investors should monitor growth sustainability closely.
Bullish
- Accelerating revenue growth: Q1 2026 revenue grew 16.7% YoY to $1,648.6M, up from $1,412.7M in Q1 2025, with sequential growth from $1,569.6M in Q4 2025. This acceleration is driven by strong TAVR and transcatheter mitral/tricuspid sales, indicating robust demand.
- High gross margin at 78.2%: Gross margin remains exceptionally high at 78.2% in Q1 2026, reflecting pricing power and efficient manufacturing. This supports strong profitability and reinvestment in R&D.
- Medicare coverage expansion catalyst: A proposed expansion of Medicare coverage for TAVR could significantly broaden patient access, directly benefiting EW as the market leader. This regulatory tailwind could drive volume growth beyond current expectations.
- Strong analyst consensus and upside: Analysts rate EW a 'Buy' with an average target of $100.96, implying ~13% upside from $89.32. The high target of $110 suggests further upside if growth accelerates.
Bearish
- High trailing P/E of 46.3x: The trailing P/E of 46.3x is well above the sector average, pricing in significant growth. If growth disappoints, the multiple could compress, leading to share price decline.
- Underperformance vs S&P 500: EW's 1-year return of +13.6% lags the S&P 500's +21.5%, and relative strength over 1 month is -8.6%. This suggests the market is not rewarding the stock as much as peers.
- Dependence on TAVR market: TAVR accounts for ~73% of revenue, making EW highly exposed to any slowdown in TAVR adoption or increased competition. A single product line concentration is a key risk.
- Potential competitive pressure: Competitors like Medtronic and Boston Scientific are advancing in TAVR and mitral/tricuspid spaces. Any market share loss could hurt growth and margins.
EW Technical Analysis
Edwards Lifesciences is in a clear uptrend over the past year, with a 1-year price change of +13.62%, though it has underperformed the S&P 500's +21.46% gain. The stock is currently trading at $89.32, which is 92.7% of its 52-week range (low: $72.30, high: $96.29), indicating it is near the upper end of its range, suggesting strong momentum but also potential overextension. The price has recovered from a low of $72.30 and is now approaching its 52-week high of $96.29, reflecting a sustained recovery from earlier weakness.
Beta
0.85
0.85x market volatility
Max Drawdown
-13.2%
Largest decline past year
52-Week Range
$72-$96
Price range past year
Annual Return
+17.5%
Cumulative gain past year
| Period | EW Return | S&P 500 |
|---|---|---|
| 1m | -0.2% | +2.4% |
| 3m | +15.4% | +4.7% |
| 6m | +16.0% | +11.7% |
| 1y | +17.5% | +21.3% |
| ytd | +7.9% | +13.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EW Fundamental Analysis
Revenue growth has been robust, with the most recent quarter (Q1 2026) showing revenue of $1,648.6 million, a 16.7% YoY increase. This growth is accelerating, as Q1 2026 revenue is up from $1,412.7 million in Q1 2025, and the trailing quarters show a consistent upward trend: Q2 2025 at $1,532.2 million, Q3 2025 at $1,553.1 million, and Q4 2025 at $1,569.6 million. The growth is driven by strong performance in Transcatheter Heart Valves, which generated $1,197.3 million in revenue, and Transcatheter Mitral and Tricuspid Therapies at $175.1 million, indicating diversified growth across key product lines.
Quarterly Revenue
$1.6B
2026-03
Revenue YoY Growth
+16.7%
YoY Comparison
Gross Margin
78.2%
Latest Quarter
Free Cash Flow
$1.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EW Overvalued?
Given that Edwards Lifesciences is profitable, the primary valuation metric is the trailing P/E ratio, which stands at 46.33x, while the forward P/E is 26.46x. This significant gap implies the market expects substantial earnings growth, as the forward multiple is much lower. The stock trades at a premium to the sector, with a P/S ratio of 8.22x and an EV/EBITDA of 33.31x, compared to industry averages, reflecting its market leadership and growth prospects. Historically, the stock's P/E has ranged from around 28x to 60x over the past few years, and the current trailing P/E of 46.33x is above the midpoint, suggesting the market is pricing in optimistic expectations, but the forward P/E of 26.46x indicates a more reasonable valuation if growth materializes.
PE
46.3x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 27x~51x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
33.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks: EW's high gross margin (78.2%) and low debt (D/E 0.068) provide a solid financial foundation, but the company's profitability is sensitive to R&D spending and operating expenses. Operating margin was 27.0% in Q1 2026, down from 33.3% in Q1 2025, indicating margin pressure from increased investments. Free cash flow is positive at $1.09B TTM, but the high trailing P/E (46.3x) leaves little room for error; any earnings miss could trigger a sharp multiple contraction. Additionally, the company does not pay a dividend, so investors rely solely on capital appreciation, increasing sensitivity to growth expectations.
FAQ
The key risks include: 1) Valuation risk: The high P/E could compress if growth slows, leading to a decline in share price. 2) Competitive risk: Medtronic and Boston Scientific are advancing in TAVR, which could erode EW's market share. 3) Regulatory risk: The Medicare expansion could be delayed or unfavorable, impacting volumes. 4) Macro risk: An economic downturn could reduce elective procedures, hurting revenue. The most severe risk is a combination of these factors, which could push the stock down to the 52-week low of $72.30.
The 12-month forecast for EW is positive, with a base case target of $100.96 (average analyst target), a bull case of $110, and a bear case of $84. The probabilities are 30% bull, 50% base, and 20% bear. The most likely scenario is the base case, where the company continues to grow revenue at 15-17% and the stock trades around $100. The key assumption is that TAVR adoption remains strong and the Medicare expansion is approved. If growth accelerates, the stock could reach $110; if growth disappoints, it could fall to $84.
EW is trading at a premium to the sector, with a trailing P/E of 46.3x, P/S of 8.2x, and EV/EBITDA of 33.3x. This is higher than the industry averages, reflecting the market's high expectations for growth. However, the forward P/E of 26.5x suggests that if the company meets earnings estimates, the valuation is more reasonable. Historically, EW's P/E has ranged from 28x to 60x, so the current level is above the midpoint. The market is pricing in strong growth, and if growth materializes, the stock is fairly valued; if not, it could be overvalued.
EW is a good buy for investors with a long-term horizon and tolerance for volatility. The stock offers a 13% upside to the average analyst target of $100.96, supported by strong revenue growth (16.7% YoY) and a high gross margin (78.2%). However, the trailing P/E of 46.3x is elevated, and the stock has underperformed the market over the past year. The main downside risk is a growth slowdown, which could lead to multiple compression. For growth-oriented investors, EW is a solid pick, but value investors may find the valuation rich.
EW is more suitable for long-term investment due to its growth potential and strong market position. The company has a beta of 0.846, indicating lower volatility than the market, but it can still experience significant swings. The stock does not pay a dividend, so returns depend on capital appreciation. For long-term investors, a holding period of at least 3-5 years is recommended to capture the growth from TAVR expansion and new product launches. Short-term traders may find opportunities around earnings and regulatory news, but the stock's volatility and valuation make it risky for short-term speculation.